Samsung Medical Center is a tertiary hospital located in Irwon-Dong of Gangnam-Gu, Seoul, South Korea. SMC is composed of Samsung Seoul Hospital, Kangbook Samsung Hospital, Samsung Changwon Hospital, and Samsung Life Sciences Research Center. SMC was founded on November 9, 1994.

During the past decade, Samsung Medical Centre; Division of Hematology/Oncology conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 15 clinical trials were completed, i.e. on average, 115.4% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 4 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Samsung Medical Centre; Division of Hematology/Oncology" #1 sponsor was "Hoffmann-La Roche" with 13 trials, followed by "Pfizer" with 5 trials sponsored, "BeiGene" with 2 trials sponsored, "Genentech, Inc." with 2 trials sponsored and "Samsung Medical Center" with 2 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Samsung Medical Centre; Division of Hematology/Oncology" #1 collaborator was "Genentech, Inc." with 3 trials as a collaborator, "Breast International Group" with 2 trials as a collaborator, "Austrian Breast and Colorectal Cancer Group" with 1 trials as a collaborator, "Chugai Pharmaceutical" with 1 trials as a collaborator and "Hoffmann-La Roche" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Samsung Medical Centre; Division of Hematology/Oncology" are "Breast Cancer" (7 trials), "Colorectal Cancer" (2 trials), "Hepatocellular Carcinoma" (2 trials), "Adult T Cell Leukemia/Lymphoma" (1 trials) and "B-cell Lymphoma" (1 trials). Many other conditions were trialed in "Samsung Medical Centre; Division of Hematology/Oncology" in a lesser frequency.

Most popular intervention types in "Samsung Medical Centre; Division of Hematology/Oncology" are "Drug" (25 trials), "Other" (3 trials), "Biological" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Docetaxel" (6 trials), "Cyclophosphamide" (5 trials), "Pertuzumab" (5 trials) and "Paclitaxel" (4 trials). Other intervention names were less common.

The vast majority of trials in "Samsung Medical Centre; Division of Hematology/Oncology" are 25 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "Samsung Medical Centre; Division of Hematology/Oncology". undefined are not yet recruiting, 4 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in Samsung Medical Centre; Division of Hematology/Oncology, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Samsung Medical Centre; Division of Hematology/Oncology, 0 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".